Search This Blog

Friday, February 22, 2019

Regeneron downgraded to Neutral from Buy at Guggenheim

Guggenheim analyst Yatin Suneja downgraded Regeneron Pharmaceuticals to Neutral after taking over coverage of the name, citing his belief that growth in its flagship Eylea product is abating and the launch of competitive products and biosimilars could lead to pricing pressure. The analyst lowered the price target for the shares to $425 from the firm’s prior $466 target.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.